8-K - Dianthus Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Dianthus Therapeutics announced an early GO decision in Phase 3 CAPTIVATE trial of claseprubart in CIDP after achieving 20 confirmed responders with less than 40 participants in Part A, and reported FY 2025 financial results including $514.4 million cash runway into 2028 and net loss of $162.3 million.

Key Takeaways

1Early GO decision in CAPTIVATE Part A with 20 confirmed responders from <40 participants, confirmed by DSMB with no related serious AEs

2Phase 3 gMG trial of claseprubart 300mg/2mL Q2W/Q4W to initiate mid-2026, top-line 2H'28

3Phase 2 MoMeNtum MMN trial top-line on track 2H'26

4Phase 1 DNTH212 healthy volunteer data expected 2H'26

5FY2025 net loss $162.3M or $4.20/share vs $85.0M or $2.55/share in 2024

6Cash $514.4M as of Dec 31, 2025 provides runway into 2028

Current Report Details

Event Type

Financial Results

Regulation Fd

Other Event

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition. On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s fin

Financial Results

7.01

of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of

Regulation Fd

8.01

. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated March 9, 2026 99.2 Data press release, dated March

Other Event

Results of Operations

Full Year 2025

Metric	Value	Basis	Prior Period
Net Loss	$162.30	GAAP	$85.00
Diluted EPS	$-4.20	GAAP	$-2.55

Exhibits (4)

8-K

99.1

EX-99.1

99.2

EX-99.2

99.3

EX-99.3